Previous 10 | Next 10 |
Amendment of Secured Loan Agreement Extends Interest-Only Period to January 2024 Amendment Defers Over $3 Million in Principal Payments Beyond 2023 Note Matures in January 2025, with Additional Extensions of the Interest-Only Period Available, Subject to Achievement of Certain Mile...
Aytu BioPharma ( NASDAQ: AYTU ) stock dipped ~5% on Oct. 13 after the company said it was indefinitely suspending certain clinical development programs, thus expecting to save over $20M. The suspension includes AR101/enzastaurin for treat Vascular Ehlers-Danlo...
Following a corporate review, Aytu BioPharma is indefinitely suspending clinical development and removing expenses related to AR101/enzastaurin, Healight, and NT0502, and focusing on revenue growth and near-term cash flow generation Aytu is expecting to generate positive quarterly Adjus...
Adzenys XR-ODT is FDA-Approved as Bioequivalent to Adderall XR Reported Supply Disruptions of Adderall XR Generic Equivalents Have the Potential to Affect Patient Access to ADHD Medications ENGLEWOOD, CO / ACCESSWIRE / October 5, 2022 / Aytu BioPharma, Inc. (the Company or "Aytu") ...
Start Time: 16:30 End Time: 17:12 Aytu BioPharma, Inc. (AYTU) Q4 2022 Earnings Conference Call September 27, 2022, 16:30 PM ET Company Participants Josh Disbrow - Chairman and CEO Mark Oki - CFO Robert Blum - Lytham Partners Conference Call Particip...
What Did The Stock Market Do Today, September 27, 2022? Whether you’re trading penny stocks or not, what’s happening in the stock market today is important. If you missed Tuesday’s session, you missed one of the wildest. The Dow and the S&P 500 (NYSEARCA: ...
Aytu BioScience press release ( NASDAQ: AYTU ): FQ4 GAAP EPS of -$0.49 misses by $0.12 . Revenue of $27.45M (+16.9% Y/Y) beats by $1.95M . Cash and cash equivalents at the end of the fiscal year ended June 30, 2022 were $19.4 million. Subsequent to the end ...
Record fourth quarter and fiscal year net revenue driven by strong growth in Prescription segment Positive Adjusted EBITDA within Prescription segment Company to Host Conference Call Today at 4:30pm ET ENGLEWOOD, CO / ACCESSWIRE / September 27, 2022 / Aytu BioPharma, Inc. (Nas...
ENGLEWOOD, CO / ACCESSWIRE / September 20, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, with a development pipeline addressing rare, pediatric-onset disorders, will report financial results for its fourth quarter and fisca...
Aytu BioPharma ( NASDAQ: AYTU ) announced on Wednesday the addition of a fourth patent for AR101/Enzastaurin to treat Vascular Ehlers-Danlos Syndrome, rare genetic disorder treatment. The patent has an expiry date of September 2041. The company expec...
News, Short Squeeze, Breakout and More Instantly...
Company receives proceeds of $3.5 million through exercise of warrants, a portion of which was used to pay down debt Interest rate on new $13.0 million term loan reduced by approximately 350 basis points today, potentially saving the Company $1.3 million over the life of the term loan T...
Phoenix, Arizona and New York, New York--(Newsfile Corp. - May 29, 2024) - Lytham Partners, a leading investor relations and corporate access firm, today announced the schedule for its Spring 2024 Investor Conference taking place virtually on May 30, 2024. More than 40 companies will be available...
DENVER, CO / ACCESSWIRE / May 23, 2024 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, CEO, will participate in a webcasted fireside chat and host one-on-one meetings with inv...